Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anemia; Sickle-Cell, With Crisis Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Safety Study of Eptifibatide in Patients With Sickle Cell Disease

NCT00834899
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 1, 2026, 9:44 AM EDT
Not yet recruiting Phase 4 Interventional

Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis

NCT07682662
View directory record Official record
Conditions
Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Interventions
Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm)
Drug · Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
2 Years to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SelG1, Placebo
Drug
Lead sponsor
Reprixys Pharmaceutical Corporation
Industry
Eligibility
16 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 1, 2026, 9:44 AM EDT
Completed No phase listed Observational

Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease

NCT06345638
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 1, 2026, 9:44 AM EDT
Not yet recruiting Phase 3 Interventional

Optimal Timing of Ketamine Initiation for SCD Pain

NCT07450430
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis
Interventions
Ketamine hydrochloride injection, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 24 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microvascular Blood Flow in Sickle Cell Anemia

NCT01566890
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
regadenoson infusion with contrast-enhanced ultrasound, contrast-enhanced ultrasound
Drug · Procedure
Lead sponsor
Versiti Blood Health
Other
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 4 Interventional Results available

Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease

NCT02222246
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hydromorphone (Standardized, weight-based dosing), Morphine Sulfate (Standardized, weight-based dosing), Hydromorphone (Patient Specific dosing), Morphine Sulfate (Patient Specific dosing)
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Phase 1Phase 2 Interventional

L-citrulline Injection in Patients Aged 6-21 Years Old with Sickle Cell Disease Presenting with Vaso-Occlusive Crisis (VOC)

NCT04852172
View directory record Official record
Conditions
Acute Vaso Occlusive Crisis (VOC)
Interventions
L-citrulline, D5 1/2NS
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

NCT05348915
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional

A Stratified Sickle Event Randomized Trial (ASSERT)

NCT00102791
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ICA-17043
Drug
Lead sponsor
Icagen
Industry
Eligibility
16 Years to 65 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
42
States / cities
Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Phase 2 Interventional Results available

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

NCT00532883
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 4 Interventional

Low Dose Ketamine and Acute Pain Crisis

NCT04330183
View directory record Official record
Conditions
Sickle Cell Crisis
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional Results available

Apixaban in Patients With Sickle Cell Disease

NCT02179177
View directory record Official record
Conditions
Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Nirmish Shah
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Oct 1, 2026, 9:44 AM EDT
Not yet recruiting Phase 3 Interventional

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

NCT06989567
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
L-citrulline, Placebo
Drug · Other
Lead sponsor
Asklepion Pharmaceuticals, LLC
Industry
Eligibility
6 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises

NCT02698761
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Crisis, Vaso-Occlusive Crises
Interventions
Comprehensive Care Plan
Other
Lead sponsor
Valley Anesthesiology Consultants
Other
Eligibility
12 Years to 18 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 2 Interventional

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

NCT00434473
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Acute Chest Syndrome
Interventions
A-001, Placebo
Drug · Other
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
5 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 1, 2026, 9:44 AM EDT
Withdrawn Phase 2 Interventional

Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC)

NCT00711698
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Patient controlled analgesia, nurse-administered intermittent IV bolus opioid therapy (NAIBOD)
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 1, 2026, 9:44 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets, Etavopivat Tablets
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 1, 2026, 9:44 AM EDT
Recruiting Not applicable Interventional

Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

NCT06184126
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Acute Pain
Interventions
Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

NCT01476696
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Prasugrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 1, 2026, 9:44 AM EDT
Completed Not applicable Interventional Results available

Hyperbaric Oxygen Therapy in Sickle Cell Pain

NCT03412045
View directory record Official record
Conditions
Vaso-occlusive Crisis, Sickle Cell Anemia Crisis
Interventions
hyperbaric oxygen therapy
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 1, 2026, 9:44 AM EDT
Terminated Phase 2 Interventional

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

NCT01522196
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis
Interventions
Varespladib, Placebo (Normal Saline)
Drug · Other
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
5 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 1, 2026, 9:44 AM EDT